Literaturverweise


  1. Curatolo P, Bombardieri R et al. Tuberous sclerosis. Lancet; 2008; 372: 657–668.
  2. Plon S. E., Owens J. Tuberous sclerosis complex: Genetics, clinical features, and diagnosis. UpToDate; zitiert am 11.06.2012.
  3. Thiele EA, Józwiak S. Natual History of Tuberous Sclerosis Complex and Overview of Manifestations. In: Kwiatkowski DJ, Whittemore VH, Thiele EA, Hrsg.: Tuberous sclerosis complex. Weinheim. Wiley-Blackwell; 2010: 11–20.
  4. Thiele EA, Weiner HL. Epilepsy in TSC. In: Kwiatkowski DJ, Whittemore VH, Thiele EA, Hrsg.: Tuberous sclerosis complex. Weinheim. Wiley-Blackwell; 2010: 187–210.
  5. Berlit P. Klinische Neurologie. 2. Aufl. Heidelberg: Springer Medizin; 2006.
  6. Prather P, Vries PJ de. Behavioral and cognitive aspects of tuberous sclerosis complex. Journal of child neurology; 2004; 19: 666–674.
  7. Winterkorn EB, Pulsifer MB et al. Cognitive prognosis of patients with tuberous sclerosis complex. Neurology; 2007; 68: 62–64.
  8.  Chu-Shore CJ, Major P et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia; 2010; 51: 1236–1241.
  9. Joinson C, O'Callaghan FJ et al. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychological medicine; 2003; 33: 335–344.
  10. Kaczorowska M, Jurkiewicz E et al. Cerebral tuber count and its impact on mental outcome of patients with tuberous sclerosis complex. Epilepsia; 2011; 52: 22–27.
  11. Rott H, Hehn H et al.; 2007. Tuberöse Sklerose: Eine Krankheit, die (auch) unter die Haut geht. Rott, Hans-Dieter (Hg.). Wiesbaden: Verl.- und Werbeges. f. polit. Meinungsbildung.
  12. Prather P, Thiele E et al. Neuropsychological profiling in tuberous sclerosis complex (TSC): Implications for neurobiology and clinical interventions. Journal of Intellectual Disability Research; 2006; 50: 788.
  13. Vries PJ de. Neurodevelopmental, Psychiatric and Cognitive Aspects of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Whittemore VH, Thiele EA, Hrsg.: Tuberous sclerosis complex. Weinheim. Wiley-Blackwell; 2010: 229–267.
  14. Vries PJ de, Hunt A et al. The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families. European child & adolescent psychiatry; 2007; 16: 16–24.
  15. Bolton PF, Park RJ et al. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain; 2002; 125: 1247–1255.
  16. Numis AL, Major P et al. Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. Neurology; 2011; 76: 981–987.
  17. Deutsches Institut für Medizinische Dokumentation und Information (Hg.). Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme: 10. Revision, German Modification, Version 2012
  18. Allroggen M, Kölch M. Tiefgreifende Entwicklungsstörungen. In: Fegert JM, Kölch M, Hrsg.: Klinikmanual Kinder- und Jugendpsychiatrie und -psychotherapie. Springer Berlin Heidelberg; 2011: 158–170.
  19. D'Agati E, Moavero R et al. Attention-deficit hyperactivity disorder (ADHD) and tuberous sclerosis complex. Journal of child neurology; 2009; 24: 1282–1287.
  20. Bruni O, Cortesi F et al. Sleep disorders in tuberous sclerosis: a polysomnographic study. Brain & development; 1995; 17: 52–56.
  21. van Eeghen AM, Numis AI et al. Characterizing sleep disorders of adults with tuberous sclerosis complex: a questionnaire-based study and review. Epilepsy & behavior : E&B; 2011; 20: 68–74.
  22. Darling TN, Moss J et al. Dermatologic Manifestations of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Whittemore VH, Thiele EA, Hrsg.: Tuberous sclerosis complex. Weinheim. Wiley-Blackwell; 2010: 285–309.
  23. Foster RS, Bint LJ et al. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. The Australasian journal of dermatology; 2012; 53: 52–56.
  24. Wataya-Kaneda M, Tanaka M et al. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. The British journal of dermatology; 2011; 165: 912–916.
  25. Józwiak S, Kotulska K et al. Clinical and genotype studies of cardiac tumors in 154 patients with tuberous sclerosis complex. Pediatrics; 2006; 118: e1146-51.
  26. Smith HC, Watson GH et al. Cardiac rhabdomyomata in tuberous sclerosis: their course and diagnostic value. Archives of disease in childhood; 1989; 64: 196–200.
  27. Jozwiak S, Respondek-Liberska M. Cardiac and Vascular Manifestations. In: Kwiatkowski DJ, Whittemore VH, Thiele EA, Hrsg.: Tuberous sclerosis complex. Weinheim. Wiley-Blackwell; 2010: 327–344.
  28. Agrawal S, Fulton AB. Ophthalmic Manifestations. In: Kwiatkowski DJ, Whittemore VH, Thiele EA, Hrsg.: Tuberous sclerosis complex. Weinheim. Wiley-Blackwell; 2010: 271–284.
  29. Salerno AE, Marsenic O et al. Vascular involvement in tuberous sclerosis. Pediatric nephrology; 2010; 25: 1555–1561.
  30. Bissler JJ, Henske EP. Renal Manifestations of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Whittemore VH, Thiele EA, Hrsg.: Tuberous sclerosis complex. Weinheim. Wiley-Blackwell; 2010: 311–325.
  31. Cook JA, Oliver K et al. A cross sectional study of renal involvement in tuberous sclerosis. Journal of medical genetics; 1996; 33: 480–484.
  32. O'Callaghan FJ, Noakes MJ et al. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU international; 2004; 94: 853–857.
  33. Bissler JJ, Kingswood JC et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet; 2013. doi: 10.1016/S0140-6736(12)61767-X. [Epub ahead of print]
  34. Hancock E, Osborne J. Lymphangioleiomyomatosis: a review of the literature. Respiratory medicine; 2002; 96: 1–6.
  35. McCormack FX, Henske EP. Lymphangioleiomyomatosis and Pulmonary Disease in TSC. In: Kwiatkowski DJ, Whittemore VH, Thiele EA, Hrsg.: Tuberous sclerosis complex. Weinheim. Wiley-Blackwell; 2010: 345–368.
  36. Henske EP, McCormack FX. Lymphangioleiomyomatosis - a wolf in sheep's clothing. The Journal of clinical investigation; 2012; 122: 3807–3816.
  37. McCormack FX, Inoue Y et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. The New England journal of medicine; 2011; 364: 1595–1606.
  38. Parker M. Families Caring for Chronically III Children with Tuberous Sclerosis Complex. Family & Community Health; 1996; 19.
  39. Raina P, O'Donnell M et al. Caregiving process and caregiver burden: conceptual models to guide research and practice. BMC pediatrics; 2004; 4: 1.
  40. Shonkoff JP, Hauser-Cram P et al. Development of infants with disabilities and their families: implications for theory and service delivery. Monographs of the Society for Research in Child Development; 1992; 57: v-vi, 1-153.
  41. Franz, D.N. (2004) Non-neurologic manifestations of tuberous sclerosis complex. J.Child Neurol., 19, 690-698
  42. Rowley, S.A., O`Callaghan, F.J. and Osborne, J.P. (2001) Ophthalmic manifestations of tuberous sclerosis: